Evaluation of Rare Tumors with [F-18]Fluorodeoxyglucose Positron Emission Tomography.
Evaluation of Rare Tumors with [F-18]Fluorodeoxyglucose Positron Emission Tomography.
复制标题
DOI：
10.1016/s1095-0397(99)00014-x
复制
发表时间：
1999-05-01
期刊：
影响因子：
--
通讯作者：
Fischman, Alan J.
中科院分区：
文献类型：
--
作者：
Jadvar, Hossein;Fischman, Alan J.
本文的目的是评价正电子发射断层扫描（PET）与2-[18 F]氟-2-脱氧-D-葡萄糖（FDG）的临床评估罕见肿瘤的实用性。在过去的18个月里，我们发现了6例罕见肿瘤患者，他们在初次诊断时接受了PET成像，进行肿瘤监测或治疗后重新评估。将PET结果与随访临床数据、其他成像方式和组织学结果进行比较。FDG PET在甲状腺未分化癌、胸膜间皮瘤、粘液样脂肪肉瘤、恶性纤维组织细胞瘤、滑膜细胞肉瘤和子宫平滑肌肉瘤患者中正确检出疾病。这些结果表明，PET是有用的各种罕见肿瘤的评估，无论是初始术前分期和治疗后的评估。进一步的经验与其他罕见的肿瘤是必要的，以确定确切的作用，FDG PET在这种临床设置。
The purpose of this paper was to evaluate the utility of positron emission tomography (PET) with 2-[18F]fluoro-2-deoxy-D-glucose (FDG) in the clinical assessment of rare tumors. We identified 6 patients over the last 18 months with rare tumors who were referred for PET imaging at the time of initial diagnosis, for tumor surveillance or for posttherapy reevaluation. The PET findings were compared with follow-up clinical data, the results of other imaging modalities and histology. FDG PET correctly detected disease in patients with anaplastic thyroid cancer, pleural mesothelioma, myxoid liposarcoma, malignant fibrous histiocytoma, synovial cell sarcoma and uterine leiomyosarcoma. These findings suggest that PET is useful in the evaluation of a variety of rare tumors both for initial preoperative staging and post-therapy assessment. Further experience with other uncommon tumors is necessary to define the precise role of FDG PET in this clinical setting.